Chinese Health Insurance Ruralization Expands Patient Pool For Clinical Trials
This article was originally published in PharmAsia News
Executive Summary
SAN FRANCISCO - China's plan to expand health insurance plans to rural areas will greatly increase access to patients for clinical trials, in turn driving market growth as more companies look to enroll patients in China, according to panelists discussing clinical trials in Asia at Cambridge Healthtech Institute's Molecular Medicine Tri-Conference in San Francisco
You may also be interested in...
NovaMed CEO Mark Lotter On Working With Pharma Distributors In China: An Interview With PharmAsia News
Shanghai-based NovaMed Pharmaceuticals was founded in August 2005 to provide distribution services for multinational pharmaceutical companies in China. NovaMed has signed China deals with several multinationals, including Baxter, Pfizer and Sanofi-Aventis. NovaMed Founder and CEO Mark Lotter recently participated in an email interview with PharmAsia News' Shanghai bureau about the changing contours of the pharmaceutical sector in China.
NovaMed CEO Mark Lotter On Working With Pharma Distributors In China: An Interview With PharmAsia News
Shanghai-based NovaMed Pharmaceuticals was founded in August 2005 to provide distribution services for multinational pharmaceutical companies in China. NovaMed has signed China deals with several multinationals, including Baxter, Pfizer and Sanofi-Aventis. NovaMed Founder and CEO Mark Lotter recently participated in an email interview with PharmAsia News' Shanghai bureau about the changing contours of the pharmaceutical sector in China.
Accelovance’s Stephen Trevisan And Robert deGroof On China’s Clinical Research Landscape: An Interview With PharmAsia News (Part 2 of 2)
[Editor's Note: This is part two of a two-part interview. Part one appeared in PharmAsia News, May 15, 2008.]